LBA48 CCTG BR.31: A Global, Double-Blind Placebo-Controlled, Randomized Phase III Study of Adjuvant Durvalumab in Completely Resected Non-Small Cell Lung Cancer (NSCLC)
Annals of Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined